NCT07246278RecruitingPhase 1/2
Celecoxib in Parkinson Disease as Adjuvant Therapy
Evaluating Safety and Efficacy of Celecoxib in Patients With PD.
Source: ClinicalTrials.gov · Last updated 5 Dec 2025
Brief summary (registry, in English)
Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 20 Nov 2025
- Primary completion date
- 20 Nov 2026
- Lead sponsor
- Tanta University
- Diseases
- Parkinson disease
- NCT number
- NCT07246278
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 80
- From 20 Nov 2025 to the primary completion date, 20 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol and / or drug abusers.
- Patients who are currently using other anti-inflammatory drugs.
Other illness
- Patients with known allergy to the study medications
- Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).
Other
- Breast feeding
- Patients with significant liver and kidney function abnormalities.
- Pregnant women and women with planned pregnancy.
Who the study is looking for
- Age ≥ 18 years.
- Both male and female will be included.
- Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Unuversity Coordinator of this site? Confirm its status | Tanta | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.